查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1807354

Tremfya 市場 - 全球產業規模、佔有率、趨勢、機會和預測，按應用（斑塊銀屑病、銀屑病關節炎等）、按配銷通路、按地區和競爭進行細分，2020-2030 年預測

Tremfya Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application (Plaque Psoriasis, Psoriatic Arthritis, Others), By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 184 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球 Tremfya 市值為 37.8 億美元，預計到 2030 年將達到 58.7 億美元，複合年成長率為 7.59%。全球 Tremfya 市場正在穩步成長，這得益於對治療斑塊狀銀屑病和乾癬性關節炎等慢性自體免疫疾病的標靶生物療法的需求不斷成長。 Tremfya 是一種 IL-23 抑制劑，因其高效、安全性高、給藥方案方便而備受關注，可提高患者依從性和治療效果。這些疾病在世界各地的盛行率不斷上升，再加上患者和醫療保健專業人員對標靶免疫療法益處的認知不斷提高，促進了市場擴張。製藥公司正在投資高級研究和臨床試驗，以探索 Tremfya 更廣泛的治療潛力，包括其在其他發炎性疾病中的應用。擴大治療指南，建議對中度至重度病例使用生物製劑，進一步提高了採用率。

市場概覽
預測期 2026-2030
2024年市場規模 37.8億美元
2030年市場規模 58.7億美元
2025-2030 年複合年成長率 7.59%
成長最快的領域 銀屑病關節炎（PsA）
最大的市場 北美洲

市場正向長效生物製劑轉變，此製劑可在維持療效的同時減少給藥頻率，與 Tremfya 的月度或季度給藥方案完美契合。生物製劑製劑和給藥系統的不斷進步，有助於提高患者的依從性和治療滿意度。製藥商和醫療保健提供者之間的合作也顯著增多，旨在加強病患教育、最佳化治療途徑，並透過保險覆蓋和報銷計畫擴大藥物可及性。持續的產品創新、產品線拓展以及旨在提升市場滲透率和滿足未滿足需求的策略合作夥伴關係，正在塑造競爭態勢。此外，隨著臨床醫生為患有複雜免疫介導疾病的患者尋求更精準、更有效的治療方案，對個人化醫療的日益關注也推動了像 Tremfya 這樣的標靶療法的發展。

儘管成長前景光明，但全球 Tremfya 市場仍面臨許多挑戰。高昂的治療費用仍然是一大障礙，尤其是在中低收入地區，這限制了患者更廣泛地獲得治療。生物相似藥的專利獨佔權和監管要求可能會在短期內限制競爭性定價，從而延長與成本相關的限制。部分患者可能出現不同的治療反應，因此需要其他治療策略。該市場面臨其他生物製劑和標靶類似途徑的小分子藥物（例如 IL-17 和 TNF 抑制劑）的激烈競爭，這可能會影響 Tremfya 在某些患者群體中的應用。此外，新適應症的核准流程冗長而複雜，可能會延誤市場擴張機會。透過定價策略、患者援助計劃和持續的臨床研究來應對這些挑戰，對於在預測期內保持成長至關重要。

關鍵市場促進因素

慢性發炎疾病盛行率上升

主要市場挑戰

治療費用高昂

主要市場趨勢

IL-23抑制劑的採用率不斷提高

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第 5 章：全球 Tremfya 市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依應用（斑塊癬、乾癬關節炎 (PsA)、其他）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按公司分類（2024）
    • 按地區
  • 市場地圖

第6章：北美 Tremfya 市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 7 章：歐洲 Tremfya 市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區 Tremfya 市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美洲 Tremfya 市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲 Tremfya 市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第13章：干擾：衝突、流行病與貿易壁壘

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章：競爭格局

  • Johnson & Johnson Services, Inc.
  • Coherus BioSciences
  • Amgen Inc.
  • AbbVie Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • AstraZeneca plc
  • Sanofi SA
  • Bristol-Myers Squibb

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 30466

The Global Tremfya Market was valued at USD 3.78 Billion in 2024 and is expected to reach USD 5.87 Billion by 2030 with a CAGR of 7.59%. The Global Tremfya Market is witnessing steady growth, driven by rising demand for targeted biologic therapies in managing chronic autoimmune conditions such as plaque psoriasis and psoriatic arthritis. Tremfya, an IL-23 inhibitor, has gained significant attention due to its high efficacy, favorable safety profile, and convenient dosing schedule, which enhance patient adherence and treatment outcomes. Growing prevalence of these conditions worldwide, coupled with increasing awareness among patients and healthcare professionals about the benefits of targeted immunology therapies, is contributing to the market's expansion. Pharmaceutical companies are investing in advanced research and clinical trials to explore the broader therapeutic potential of Tremfya, including its application in other inflammatory disorders. Expanding treatment guidelines that recommend biologics for moderate-to-severe cases are further boosting adoption rates.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 3.78 Billion
Market Size 2030USD 5.87 Billion
CAGR 2025-20307.59%
Fastest Growing SegmentPsoriatic Arthritis (PsA)
Largest MarketNorth America

The market is experiencing a shift toward long-acting biologics that reduce dosing frequency while maintaining therapeutic effectiveness, aligning well with Tremfya's monthly or quarterly administration schedule. Continuous advancements in biologic drug formulation and delivery systems are supporting better patient compliance and treatment satisfaction. There is also a notable increase in collaborations between pharmaceutical manufacturers and healthcare providers to improve patient education, optimize treatment pathways, and expand access through insurance coverage and reimbursement programs. Competitive dynamics are being shaped by ongoing product innovation, pipeline expansions, and strategic partnerships aimed at enhancing market penetration and addressing unmet needs. Furthermore, the increasing focus on personalized medicine is encouraging the development of targeted therapies like Tremfya, as clinicians seek more precise and effective treatment options for patients with complex immune-mediated diseases.

Despite the promising growth prospects, the Global Tremfya Market faces several challenges. High treatment costs remain a major barrier, particularly in low- and middle-income regions, limiting broader patient access. Patent exclusivity and regulatory requirements for biosimilars may restrict competitive pricing in the near term, prolonging cost-related limitations. Some patients may also experience varying treatment responses, necessitating alternative therapeutic strategies. The market is subject to intense competition from other biologics and small molecule drugs targeting similar pathways, such as IL-17 and TNF inhibitors, which may impact Tremfya's adoption in certain patient segments. Additionally, the lengthy and complex drug approval process for new indications can delay market expansion opportunities. Addressing these challenges through pricing strategies, patient assistance programs, and continued clinical research will be crucial for sustaining growth in the forecast period.

Key Market Drivers

Rising Prevalence of Chronic Inflammatory Diseases

The rising prevalence of chronic inflammatory diseases such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis is a compelling driver for the Global Tremfya Market. In the United States, psoriasis affects approximately 3.0% of adults, translating to over 7.5 million individuals, according to data from the National Health and Nutrition Examination Survey. Among these, a significant portion go on to develop psoriatic arthritis, which impacts roughly 0.41% of the U.S. adult population, equating to nearly 912,000 adults.

Inflammatory bowel diseases (IBD), encompassing Crohn's disease and ulcerative colitis, are diagnosed in approximately 721 per 100,000 Americans, or nearly 1 in 100, as reported by the Crohn's & Colitis Foundation in a comprehensive U.S. population-based study. Strong diagnostic data reinforces the growing burden of these conditions. These diseases are often chronic and debilitating, underscoring the importance of effective long-term treatment strategies. Tremfya's targeted mechanism of selectively inhibiting the p19 subunit of interleukin-23 addresses the underlying inflammatory pathways more precisely than older systemic therapies. This precision results in favorable safety and efficacy outcomes, making Tremfya an appealing treatment for both clinicians and patients seeking better disease control and improved quality of life.

Rising obesity rates, environmental stressors, and an aging population contribute to increasing incidence and prevalence of these immune-mediated conditions. Healthcare systems emphasize early intervention to prevent disease progression, reduce flare-ups, and minimize complications such as joint damage or gastrointestinal scarring. Demand remains strong for biologics like Tremfya that offer durable remission and reduced dosing frequency. Altogether, the confluence of growing patient populations supported by robust U.S. epidemiological data and Tremfya's effective, targeted profile is fueling market momentum and positioning it as a preferred therapy in managing chronic inflammatory diseases.

Key Market Challenges

High Treatment Costs

High treatment costs remain one of the most significant challenges impacting the Global Tremfya Market. Tremfya, being a biologic therapy, involves complex manufacturing processes, stringent quality controls, and advanced biotechnology infrastructure, all of which contribute to its high price point. The expense is further amplified by research and development costs, clinical trial investments, and regulatory compliance requirements. For many patients, particularly in low- and middle-income countries, the price of Tremfya places it beyond financial reach without robust insurance coverage or government subsidy programs. Even in developed markets, patients may face high out-of-pocket expenses, co-payments, or limitations in reimbursement policies, which can result in reduced adoption rates.

Healthcare systems often prioritize cost-effectiveness, and biologics like Tremfya must demonstrate clear value over existing therapies to justify coverage. This economic barrier can lead to delayed treatment initiation, therapy discontinuation, or a preference for cheaper alternatives, even if they are less effective. Pharmaceutical companies face the challenge of balancing innovation with affordability while navigating pricing negotiations with payers. The high treatment cost issue also influences competitive dynamics, as the emergence of biosimilars or alternative biologics with lower prices could erode market share. Addressing this challenge requires strategic pricing, value-based reimbursement models, and expansion of patient assistance programs to make Tremfya more accessible.

Key Market Trends

Increasing Adoption of IL-23 Inhibitors

The increasing adoption of IL-23 inhibitors is emerging as a defining trend in the Global Tremfya Market, driven by the growing recognition of their targeted therapeutic benefits in treating chronic immune-mediated inflammatory diseases. IL-23 inhibitors, such as Tremfya, block the p19 subunit of the interleukin-23 cytokine, a critical driver of inflammation in conditions like plaque psoriasis and psoriatic arthritis. This highly specific mechanism of action offers a favorable efficacy-to-safety ratio, making these drugs an attractive option for both physicians and patients, particularly those who have experienced suboptimal responses or adverse effects with older biologic classes such as TNF-alpha inhibitors or IL-17 blockers. The extended dosing intervals associated with IL-23 inhibitors, often every eight to twelve weeks after initial loading doses, enhance treatment adherence by reducing the frequency of injections, which is a significant advantage for patients managing lifelong conditions.

Clinical trial data and real-world evidence continue to validate the long-term durability of response and low immunogenicity risk, further building confidence in this drug class. Pharmaceutical companies are also expanding the scope of IL-23 inhibitor applications into new indications such as Crohn's disease and ulcerative colitis, which could substantially broaden their market potential. As prescriber familiarity grows and healthcare systems begin to recognize their long-term cost-effectiveness due to reduced disease flare-ups and improved quality of life, the uptake of IL-23 inhibitors is expected to accelerate. Strategic marketing efforts, patient support programs, and increased payer acceptance are contributing to their growing presence in treatment guidelines, reinforcing the trajectory of sustained adoption for Tremfya and its counterparts in the coming years. This trend reflects a broader shift in autoimmune disease management toward precision-targeted biologics that prioritize sustained remission, minimal side effects, and improved patient convenience.

Key Market Players

  • Johnson & Johnson Services, Inc.
  • Coherus BioSciences
  • Amgen Inc.
  • AbbVie Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • AstraZeneca plc
  • Sanofi S.A.
  • Bristol-Myers Squibb

Report Scope:

In this report, the Global Tremfya Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tremfya Market, By Application:

  • Plaque Psoriasis
  • Psoriatic Arthritis (PsA)
  • Others

Tremfya Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Tremfya Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tremfya Market.

Available Customizations:

Global Tremfya Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Tremfya Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Plaque Psoriasis, Psoriatic Arthritis (PsA), Others)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.3. By Company (2024)
    • 5.2.4. By Region
  • 5.3. Market Map

6. North America Tremfya Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Tremfya Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Mexico Tremfya Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Canada Tremfya Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By Distribution Channel

7. Europe Tremfya Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Tremfya Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. Germany Tremfya Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Tremfya Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Tremfya Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Tremfya Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By Distribution Channel

8. Asia-Pacific Tremfya Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Tremfya Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Tremfya Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. South Korea Tremfya Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. Japan Tremfya Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Tremfya Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By Distribution Channel

9. South America Tremfya Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Tremfya Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. Argentina Tremfya Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. Colombia Tremfya Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Tremfya Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Tremfya Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Saudi Arabia Tremfya Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. UAE Tremfya Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Johnson & Johnson Services, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Coherus BioSciences
  • 15.3. Amgen Inc.
  • 15.4. AbbVie Inc.
  • 15.5. Novartis AG
  • 15.6. Eli Lilly and Company
  • 15.7. Pfizer Inc.
  • 15.8. AstraZeneca plc
  • 15.9. Sanofi S.A.
  • 15.10. Bristol-Myers Squibb

16. Strategic Recommendations

17. About Us & Disclaimer